BASF (OTCQX:BASFY) shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the stock did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases.
The situation is different for the biotech company Cardiol Therapeutics (TSX:CRDL). The analysts at Canaccord believe the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter.
TUI Group (OTCPK:TUIFF) stock has been on a roll for several months now. Will share prices continue to rise with the increase in temperatures? Management is certainly optimistic about the future.
Cardiol Therapeutics: High cash ratio and high price target
Ahead of important study data readout, analysts are positioning themselves for Cardiol Therapeutics. After First Berlin had already set a price target of USD 3.60 and thus saw a price potential of around 100%, the experts at Canaccord have gone one better. They believe the fair value of the specialist for diseases of the cardiovascular system is USD 6.00 per share. The stock is currently trading at USD 1.88. This values the biotech company at around USD 110 million. A high cash ratio must be taken into account here. As of the end of December 2023, the company had a cash balance of approximately CAD 35 million. From the company’s perspective, they are fully financed to fund operations until 2026.
But where does the analysts’ optimism come from that Cardiol’s share price will soon rise? Both expect positive study data in the second quarter. In early February, Cardiol announced that recruitment for the Phase II open-label study of its drug candidate CardiolRx™ for the treatment of inflammation of the pericardium (pericarditis) had been completed. In addition, CardiolRx™ received FDA approval as an orphan drug for rare diseases (Orphan Drug Designation). If the ongoing data is successful, expected in the second quarter of 2024, this will potentially shorten the path to approval.
Cardiol is also making progress with CardiolRx™ for a second rare disease indication. Patient recruitment for the ARCHER trial of CardiolRx™ in acute myocarditis (inflammation of the heart muscle) has exceeded 50% enrollment and is progressing to be completed in the third quarter of 2024. The ARCHER trial is expected to enroll 100 patients at leading cardiac centers in North America, Europe, Latin America, and Israel. The Phase II trial will investigate the safety and tolerability of CardiolRx™, as well as its impact on myocardial recovery, in patients presenting with acute myocarditis.
Shareholders can, therefore, look forward to a lively news flow throughout the current year.
TUI: Welcome back to Germany
Not only is the news flow currently positive for TUI, but the share is also picking up speed. In just six months, the tourism group’s share price has risen by almost 70%. After facing financial difficulties and a botched capital increase in 2023, inclusion in the MDAX could soon follow. Since last Monday, the world’s largest tourism company has once again become a German company on the stock exchange – the initial listing on the London Stock Exchange, which had been in place since 2014, has been discontinued. Inclusion in the MDAX could follow in June.
TUI is also doing well operationally at the moment. TUI CEO Sebastian Ebel said on the occasion of the IPO in Frankfurt: “We want to expand our international presence, continue to grow profitably and support this growth with simple structures. We are entering the summer with healthy optimism.”
**In the current year, the company expects at least as many customers as before the outbreak of the Corona pandemic in the record year of 2019, when there were around 20 million travellers. TUI aims to increase turnover by at least 10% to around EUR 23 billion in the current year. Adjusted operating profit is even expected to climb by at least 25% to EUR 1.2 billion.
According to the analysts at Morgan Stanley, the TUI share still has room for improvement with these prospects. Their target price is EUR 10. The share is currently trading at around EUR 8.
Analysts have less confidence in BASF shares. However, to the surprise of many, it has already performed well in recent months, with an increase of just over 30% in the past six months. With a price of almost EUR 54, the room for further growth seems limited. While Citigroup analysts raised their old price target from EUR 46 on Monday, their new target of EUR 55 is “only” at the current level. Only Redburn sees significant upside potential for the chemical group. The relatively unknown analyst firm caused a stir with a price target increase from EUR 41 to EUR 72. Their rating was adjusted from “Neutral” to “Buy.” The analysts believe that BASF is at the beginning of a new growth phase and, therefore, considers the company significantly undervalued.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the company at any time (hereinafter each a “Transaction”). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Join the discussion: Head over to the Bullboards at Stockhouse’s stock forums and message boards to share your market outlook and hear what everyone is saying about these and other stocks.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
